Patients Enrolled (N=156)

Placebo Group (N=52)
- Discontinued (n=11)
  - Adverse Event: 4
  - Clinical Relapse: 0
  - Entry Criteria Not Met: 0
  - Lack of Efficacy: 1
  - Lost to Follow Up: 0
  - Physician Decision: 0
  - Protocol Violation: 1
  - Subject Decision: 5
- Completed Study (n=41)

Olanzapine Group (N=104)
- Discontinued (n=18)
  - Adverse Event: 10
  - Clinical Relapse: 0
  - Entry Criteria Not Met: 0
  - Lack of Efficacy: 0
  - Lost to Follow Up: 1
  - Physician Decision: 0
  - Protocol Violation: 0
  - Subject Decision: 7
- Completed Study (n=86)